MiR-16 directly targets the three KRAS downstream effectors MAPK3, MAP2K1, and CRAF in NSCLC, restoring sensitivity to erlotinib in KRAS-mutated NSCLC both in vitro and in vivo. Here, MAP2K1 is linked to non-small cell lung carcinoma.